L-arginine

L-Arginine: A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Chemical Properties

L-arginine (C₆H₁₄N₄O₂), or 2-amino-5-guanidino-pentanoic acid, is a conditionally essential amino acid in mammals that is physiologically active in the L-form. It is synthesized from glutamine, glutamate, and proline via the intestinal-renal axis in humans. The molecule carries the formula (H₂N)(HN)CN(H)(CH₂)₃CH(NH₂)CO₂H, and features a guanidino group appended to a standard amino acid framework. At physiological pH, the carboxylic acid is deprotonated and both the amino and guanidino groups are protonated, resulting in a cation. Only the L-arginine enantiomer — abbreviated as Arg or R — is found naturally. L-arginine is the most nitrogen-rich amino acid, acting as a key precursor for the synthesis of nitrogen-containing metabolites and an essential intermediate in the clearance of excess nitrogen. Arginine's side chain possesses a guanidino group which plays a primary role in nitrogen excretion (urea), cellular signaling (nitric oxide), and energy buffering (phosphocreatine).

Classification: Essential, Non-Essential, or Conditionally Essential?

In mammals, L-arginine is classified as a semiessential or conditionally essential amino acid, depending on the developmental stage and health status of the individual. Because L-arginine can be synthesized endogenously from L-citrulline, it is classified as a nonessential amino acid in adults; however, in children and in individuals with certain conditions such as infection or trauma, L-arginine synthesis may become compromised. Arginine is not a traditional "essential" amino acid, but becomes a conditionally essential amino acid during periods of stress including burns and trauma.

Common Supplement Forms and Preparations

L-arginine occurs naturally in the L(+) form and is commercially available as the glutamate and hydrochloride salts. The vast majority of arginine supplements contain L-arginine in the form of L-arginine hydrochloride (L-arginine HCl). The hydrochloride moiety makes up approximately 17% of the molecular weight of this compound. Some product labels include the HCl portion in the stated amount of L-arginine, while others do not. L-arginine is available as a dietary supplement in various strengths and dosage forms; since it is an amino acid, it is also found in many protein powders, and may be included in products that contain other ingredients such as caffeine and vitamins.

2. Natural Sources

Dietary Sources

Approximately 80% of arginine comes from dietary intake of proteins and body protein breakdown. The remaining arginine comes from endogenous de novo production in the kidneys. Sources of amino acid arginine are meats (e.g., seafood, pork), milk and milk products, chocolate, watermelon, legumes (e.g., soybeans, chickpeas), oats and wheats, and nuts (e.g., peanuts, walnuts). Animal sources of arginine include meat, dairy products, and eggs, and plant sources include seeds of all types — for example grains, beans, and nuts.

Endogenous Biosynthesis

L-arginine is synthesised from glutamine, glutamate, and proline via the intestinal-renal axis in humans and most other mammals. It can be derived from proline or glutamate, with the ultimate synthetic step catalyzed by argininosuccinate lyase. Most human cells do not synthesize sufficient arginine to meet demand and are dependent on exogenous arginine. This gives renal cells the ability to support the systemic arginine levels through the conversion of dietary citrulline to arginine. Dietary arginine intake by the average American adult has been estimated to be 5.4 g/day.

3. Historical and Traditional Use

Discovery and Early Biochemical Research

L-arginine was first identified in extracts of etiolated lupine seedlings by Schulze and Steiger in 1886; it was shown to be a product of protein hydrolysis by Hedin nine years later, and its structure was not proven until 1910 by Sorenson. In a simpler era dating back to the mid-1980s, L-arginine seemed to be just another amino acid, notable principally for its guanido group, which conferred arginine with a high pKa and provided its distinction as one of the three basic amino acids.

A century after its first isolation from lupin seedlings, L-arginine was identified in 1988 as the physiological precursor for nitric oxide (NO) synthesis in animal cells. NO is the major endothelium-derived relaxing factor, a mediator of immune responses, a neurotransmitter, a cytotoxic free radical, and a widespread signaling molecule in the body. The discovery of NO synthesis stimulated enormous interest in the biochemistry, nutrition, and pharmacology of arginine.

The discovery of arginine as the nitrogen source of nitric oxide (Palmer et al., 1988) reinvigorated basic and clinical research on arginine and its potential uses as a nutraceutical or dietary supplement. Arginine is a conditionally essential amino acid that plays a number of critical roles in human health and disease.

Clinical and Supplemental Use

Prior to the identification of its role in NO synthesis, arginine was studied primarily in the context of nitrogen balance, the urea cycle, and clinical nutrition, particularly in parenteral and enteral feeding for surgical and trauma patients. Detrimental effects of arginine starvation on human T lymphocytes were first described in 1968 by the establishment of a causal relationship between arginine depletion and impaired in vitro activation of lymphocytes. Animal experimentation revealed that arginine administration prevents thymic involution after surgery and increases lymphocyte counts. Moreover, it became clinically apparent that there is an arginine requirement for proper wound healing. Pursuant to such observations of arginine's immunostimulatory effects, dietary arginine supplementation gained attention, with the aim of creating so-called immune-enhancing diets.

4. Key Constituents and Mechanisms of Action

Nitric Oxide Synthesis

L-arginine is the sole precursor of nitric oxide (NO) in humans and many other animals. Through the action of NO synthases, L-arginine is converted into the endothelium-derived relaxing factor (EDRF), which has been identified as NO. NO is formed from L-arginine via the enzyme nitric oxide synthase (NOS), and the effects of NO are mainly mediated by 3′,5′-cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate (GTP).

L-arginine is the exclusive substrate for nitric oxide synthase (NOS), which generates the signaling molecule nitric oxide. NO plays a critical role in the circulation by decreasing vascular tone, platelet and leukocyte activation, smooth muscle cell proliferation, extracellular matrix deposition, and endothelial cell death. NOS acts through three primary pathways: endothelial NOS (eNOS) in blood vessel walls, neuronal NOS (nNOS) in nerve tissue, and inducible NOS (iNOS) in immune cells.

The Urea Cycle

Arginine is required to maintain the urea cycle in the active state to detoxify ammonia. Arginase is the focal enzyme of the urea cycle, hydrolyzing L-arginine to urea and L-ornithine. Arginine is also required for the detoxification of ammonia, which is an extremely toxic substance for the central nervous system.

Creatine, Polyamines, Proline, and Agmatine Synthesis

Arginine is one of the most versatile amino acids in animal cells, serving as a precursor for the synthesis not only of proteins but also of nitric oxide, urea, polyamines, proline, glutamate, creatine, and agmatine. L-arginine is catabolized by arginases, nitric oxide synthases, arginine:glycine amidinotransferase, and possibly also by arginine decarboxylase, resulting ultimately in the production of urea, proline, glutamate, polyamines, nitric oxide, creatine, or agmatine. Arginine's side chain possesses a guanidino group which plays a primary role in nitrogen excretion (urea), cellular signaling (nitric oxide), and energy buffering (phosphocreatine). The post-translational modification of protein-incorporated arginine by guanidino-group methylation also contributes to epigenetic gene control.

mTOR Signaling and Protein Synthesis

Arginine also activates cellular mechanistic target of rapamycin (mTOR) and focal adhesion kinase cell signaling pathways in mammals, thereby stimulating protein synthesis, inhibiting autophagy and proteolysis, enhancing cell migration and wound healing, promoting spermatogenesis and sperm quality, and augmenting the production of milk proteins.

The Arginine Paradox and ADMA

Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of NO synthase. ADMA inhibits vascular NO production in concentrations found in pathophysiological conditions and also causes local vasoconstriction when infused intraarterially. Plasma ADMA levels are increased in humans with hypercholesterolemia, atherosclerosis, hypertension, chronic renal failure, and chronic heart failure. Increased ADMA levels are associated with reduced NO synthesis as assessed by impaired endothelium-dependent vasodilation. Among potential therapeutic strategies, administration of L-arginine has been shown to improve endothelium-dependent vascular functions in subjects with high ADMA levels. It appears that only subjects with poor NO synthesis are likely to benefit from L-arginine supplementation.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health: Blood Pressure

A systematic review and dose-response meta-analysis of randomized clinical trials published in Advances in Nutrition investigated the effect of L-arginine supplementation on blood pressure in adults. The 22 clinical trials included used oral intake of L-arginine, had at least a four-day intervention duration, included only adult humans (≥18 years old), and provided means and standard deviations for both systolic blood pressure (SBP) and diastolic blood pressure (DBP). These studies were published between 1996 and 2021 across 12 countries. The studies comprised 431 participants in the intervention group and 394 in the placebo group for SBP.

No significant changes in blood pressure were observed with dosages >9 g/d, trial duration >24 days, or in obese individuals. L-arginine supplementation also appears to decrease DBP more effectively in females than in males. Despite use of L-arginine in translational studies, the heterogeneity in terms of design elements and outcomes between and within human randomized control trials poses a significant challenge for meta-analysis inclusion.

A systematic review focused on the functional role of arginine in the regulation of endothelial function and vascular tone, examining both clinical and preclinical studies analyzing the effects of arginine supplementation in hypertension, ischemic heart disease, aging, peripheral artery disease, and diabetes mellitus. Overall, the evidence suggests that L-arginine may produce modest blood pressure reductions, with the most consistent effect observed in individuals with pre-existing cardiovascular risk factors or endothelial dysfunction.

5.2 Cardiovascular Health: Myocardial Infarction — A Critical Safety Finding

The use of the amino acid supplement L-arginine following a heart attack does not improve certain cardiac functions and may be associated with an increased risk of death, according to a study published in JAMA. Dr. Steven P. Schulman and colleagues randomized 153 patients following a first ST-segment elevation MI to receive L-arginine (with a goal dose of 3 g, three times daily) or placebo. Mortality at six months was higher in the L-arginine group (8.6% vs. 0%, p=0.01), as was the composite of death, myocardial infarction, and hospitalization for heart failure (16.7% vs. 10.1%). The trial was discontinued early at the recommendation of the data safety monitoring board due to increased mortality in the L-arginine group. The authors concluded that "L-arginine therapy should not be given to patients following a myocardial infarction."

5.3 Erectile Dysfunction

Erection is a neurovascular event in which a key mediator is nitric oxide (NO). There is reduced NO bioactivity in erectile dysfunction, and L-arginine, as a natural precursor of NO, may have a positive effect on NO production.

A systematic review and meta-analysis — described as the first of its kind on this topic — found that the primary outcome measure was ED improvement as assessed by IIEF-15 subdomain scores. The results suggested that arginine, compared with placebo or no treatment, improves erectile dysfunction of mild to moderate severity.

L-arginine has been studied alone as well as in combination with various other molecules for the treatment of erectile dysfunction, but the studies are very limited in number and have very small sample sizes. Positive evidence is available for the efficacy of L-arginine and its various combinations. Further research with larger sample sizes and standardized tools are required to recommend the routine use of these products in erectile dysfunction.

One early controlled crossover study examined L-arginine as a first-line monotherapy: 32 patients (mean age 51.6 years) with mixed-type impotence were enrolled in a randomized, placebo-controlled, crossover comparison of an oral placebo with 3 × 500 mg L-arginine/day. No statistical difference in impotence scores was found, and no drug-related adverse effects occurred with L-arginine treatment. The conclusion was that oral L-arginine 3 × 500 mg/day is not better than placebo as a first-line treatment for mixed-type impotence. The overall evidence for erectile dysfunction is thus preliminary: positive signals exist at higher doses and in combination preparations, but the trial quality and size remains limited.

5.4 Exercise Performance and Athletic Capacity

Nitric oxide-related ergogenic aids such as arginine have been shown to impact positively on sport performance through several physiological and metabolic mechanisms. However, research results have shown to be controversial. The great differences regarding required metabolic pathways and physiological demands between aerobic and anaerobic sport disciplines could be the reasons.

One meta-analysis indicated that the supplementation of L-arginine could increase VO₂max in healthy people. However, studies on the association between L-arginine supplementation and VO₂max reported contradictory results, therefore necessitating systematic review.

Arginine supplementation has been shown to alleviate endothelial dysfunction and improve exercise performance through increasing nitric oxide production in patients with cardiopulmonary diseases. In addition, arginine supplementation could decrease accumulations of lactate and ammonia, metabolites involved in the development of muscular fatigue.

One small crossover study tested 10 elite male college judo athletes who consumed 6 g/day arginine or placebo for 3 days then performed an intermittent anaerobic exercise test on a cycle ergometer; the results were null for nitric oxide production or performance in that well-trained population. Overall, the evidence for exercise performance in healthy, well-trained athletes is mixed to weak, while patients with underlying cardiovascular or pulmonary limitation may experience greater benefit.

5.5 Wound Healing and Immune Function

Arginine has been shown to enhance wound healing and T-cell-mediated immune function in rodents. One human study examined the effect of oral arginine supplementation on collagen synthesis and T-cell function in 36 healthy, non-smoking subjects. Arginine supplementation significantly enhanced the amount of collagen deposited into a standardized wound. In parallel, arginine supplementation at both doses increased lymphocyte mitogenesis in response to phytohemagglutinin and concanavalin A. The data suggest that arginine may be of clinical benefit in improving wound healing and immune responses.

Animal experimentation revealed that arginine administration prevents thymic involution after surgery and increases lymphocyte counts. Moreover, it became clinically apparent that there is an arginine requirement for proper wound healing. Arginine activates cellular mTOR and focal adhesion kinase cell signaling pathways, thereby stimulating protein synthesis and enhancing cell migration and wound healing. Clinical evidence in humans is supportive but relatively limited to small trials; the mechanistic basis is well established.

5.6 Pregnancy: Preeclampsia and Fetal Growth

In comparison to controls, providing oral L-arginine to women with a history of poor pregnancy outcomes significantly reduced risks of intrauterine growth retardation neonates, pre-term birth, and respiratory distress syndrome, and significantly increased birthweight and gestational age. L-arginine significantly increased Apgar score in women at high risk of preeclampsia or with preeclampsia or gestational or mild chronic hypertension in comparison to controls. The quality of evidence was at least medium or high. Consequently, oral L-arginine may be at least moderately recommended for women with a history of poor pregnancy outcomes and at high risk of preeclampsia or with preeclampsia or gestational or mild chronic hypertension.

5.7 Endothelial Function, Peripheral Arterial Disease, and Atherosclerosis Risk Factors

Decreased bioavailability of NO is a common mechanism involved in the pathogenesis of various vascular disorders, including hypertension, atherosclerosis, diabetes, and ischemia-reperfusion injury. Clinical and experimental studies demonstrate that L-arginine administration restores NO synthesis and vascular function in several cardiovascular disease states. Early evidence suggests that L-arginine supplementation may help treat individuals with atherosclerosis risk factors, such as hypercholesterolemia, hypertension, diabetes mellitus, kidney failure, hyperhomocysteinemia, smoking, and aging — all conditions associated with reduced NO biosynthesis.

At least two important randomized placebo-controlled clinical studies showed that 6-month L-arginine supplementation did not show any beneficial effects but harmful effects or increased mortality in patients with peripheral arterial disease and myocardial infarction on top of clinical medications. Despite the uncertain and controversial results, L-arginine supplementation is still considered as beneficial for health by some researchers.

6. Body Systems and Health Areas Associated with L-Arginine

• Cardiovascular System: NO plays a critical role in the circulation by decreasing vascular tone, platelet and leukocyte activation, smooth muscle cell proliferation, extracellular matrix deposition, and endothelial cell death.
• Renal System: L-arginine is synthesized via the intestinal-renal axis, with the kidneys playing a central role in systemic arginine homeostasis.
• Immune System: NO plays very important roles in the cardiovascular system, immune system, and nervous system.
• Reproductive System: The results of both experimental and clinical studies indicate that arginine is a nutritionally essential amino acid for spermatogenesis, embryonic survival, and fetal and neonatal growth.
• Musculoskeletal System: Arginine activates mTOR signaling pathways, thereby stimulating protein synthesis and inhibiting autophagy and proteolysis.
• Nervous System: NO is a neurotransmitter and a widespread signaling molecule in the body.
• Nitrogen Metabolism: L-arginine is the most nitrogen-rich amino acid, acting as a key precursor for the synthesis of nitrogen-containing metabolites and an essential intermediate in the clearance of excess nitrogen.

7. Dosage Forms and Doses Reported in Studies

The vast majority of arginine supplements contain L-arginine in the form of L-arginine hydrochloride (L-arginine HCl). In clinical trials, doses have varied considerably across indications:

• Blood pressure studies: The 22 clinical trials included used oral intake of L-arginine with at least a four-day intervention duration in adult humans. No significant changes were observed with dosages >9 g/d or trial duration >24 days.
• Erectile dysfunction (monotherapy trial): 32 patients were enrolled in a randomized crossover comparison using 3 × 500 mg L-arginine per day (total 1,500 mg/day).
• Post-MI trial (VINTAGE MI): Patients were randomized to receive L-arginine with a goal dose of 3 g, three times daily (9 g/day total), or placebo.
• Exercise performance study: Subjects consumed 6 g/day arginine or placebo for 3 days before exercise testing.
• Wound healing studies: Doses tested included arginine aspartate and arginine hydrochloride formulations, with hydroxyproline as an index of new collagen synthesis showing significant differences between groups.

General guidelines in clinical literature describe a typical dosage range from 2 to 6 grams per day, divided into two or three doses for adults.

8. Safety Considerations and Drug Interactions

General Tolerability

Common side effects include diarrhea and an upset stomach, especially with high doses. Reported adverse effects include cardiovascular flushing, low blood pressure, headache, nausea, vomiting, diarrhea, abdominal pain, bloating, increased uric acid, blood abnormalities, and allergic reaction.

Post-Myocardial Infarction — Contraindication

The VINTAGE MI study demonstrated that 6 months of L-arginine added to standard postinfarct medications did not reduce noninvasive measures of vascular stiffness, improve ejection fraction, or improve clinical outcomes. To the contrary, a possible increased risk of death was noted in older patients after infarction while taking L-arginine compared with those taking a placebo, leading to the early termination of the study. Mortality at six months was higher in the L-arginine group (8.6% vs. 0%, p=0.01). This is one of the most clinically significant safety signals in the L-arginine literature.

Herpes Simplex Virus

There is some thought that the ratio of lysine to arginine in the diet can affect whether or not latent herpes viruses appear. Some practitioners recommend increasing lysine and decreasing arginine to help prevent the recurrence of symptoms associated with herpes simplex virus. People with a history of cold sores or herpes simplex virus infections should exercise caution, as L-arginine may trigger viral reactivation.

Renal Disease and Electrolytes

Arginine has been found to increase potassium levels in patients with kidney disease, which can result in an irregular heartbeat. Arginine should be avoided or used with caution in patients with allergies, asthma, cold sores or genital herpes, kidney disease, and recent heart attack.

Drug Interactions

L-arginine's ability to lower blood pressure becomes a risk when combined with medications that do the same thing. Nitrates (nitroglycerin, isosorbide) both work through the nitric oxide pathway. Combining them can cause a sharp, potentially dangerous drop in blood pressure, and this combination should be avoided without medical supervision. Blood pressure medications (ACE inhibitors, beta-blockers, calcium channel blockers) may have their effects amplified by arginine. Adding arginine without adjusting medication in patients on antihypertensives can cause hypotension — dizziness, lightheadedness, or fainting.

Arginine should be avoided or used with caution in patients suffering from cirrhosis of the liver, guanidinoacetate methyltransferase deficiency, herpes, low blood pressure, recent heart attack, kidney disease, diabetes, or prior to surgery.

The "Arginine Paradox" and Limitations of Supplementation in Healthy Individuals

It appears that only subjects with poor NO synthesis are likely to benefit from L-arginine supplementation. Abundant in many types of food, synthesized from simple precursors, or recycled in different tissues in the body, arginine is classified as a nonessential amino acid; except under extreme conditions, nutritional states of arginine deficiency are rare. Most people seem to have enough arginine in their bodies already. This phenomenon — wherein supplemental arginine improves vascular function despite plasma arginine concentrations already exceeding the K_m of eNOS — is explained by elevated ADMA in diseased states, which competes with arginine for NOS binding and can be overcome by increasing substrate concentration.

References

• PubChem CID 6322 – L-Arginine, NIH/NLM
• Drugs.com Natural Products Database – L-Arginine
• ScienceDirect Topics – Arginine (Food Science Overview)
• Cynober, L. (2002). The metabolic basis of arginine nutrition and pharmacotherapy. Biomedicine & Pharmacotherapy. ScienceDirect
• Loscalzo J. (2013). R is for Arginine. Circulation. American Heart Association
• Cooke JP, Dzau VJ. (2000). What We Know and Don't Know About L-Arginine and NO. Circulation. American Heart Association
• Wu G. (2021). Role of L-Arginine in Nitric Oxide Synthesis and Health in Humans. Advances in Experimental Medicine and Biology. PubMed/PMC
• Arginine: at the crossroads of nitrogen metabolism. PMC/NIH
• Morris SM Jr. (2004). Enzymes of arginine metabolism. Journal of Nutrition. PubMed
• Wu G & Morris SM Jr. (1998). Arginine metabolism: nitric oxide and beyond. Biochemical Journal. PubMed
• Wu G et al. (2009). Arginine metabolism and nutrition in growth, health and disease. British Journal of Nutrition. PMC/NIH
• Caldwell RB et al. (2007). Arginase: A Critical Regulator of Nitric Oxide Synthesis and Vascular Function. Seminars in Perinatology. PMC/NIH
• Argininosuccinate synthase: at the center of arginine metabolism. PMC/NIH
• Shiraseb F et al. (2022). Effect of l-Arginine Supplementation on Blood Pressure in Adults: A Systematic Review and Dose-Response Meta-analysis of Randomized Clinical Trials. Advances in Nutrition. PubMed
• Assessment of Registered Clinical Trial Designs: L-Arginine and/or L-Citrulline Interventions for Hypertension. PMC/NIH 2024
• Gambardella J et al. (2020). Arginine and Endothelial Function. Biomedicines. MDPI
• Böger RH. (2004). Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox." PubMed
• Atzler D et al. (2018). ADMA, SDMA and hArg: The ADMA, SDMA and hArg paradoxes. PMC/NIH
• Schulman SP et al. (2006). L-Arginine Therapy in Acute Myocardial Infarction: The VINTAGE MI Randomized Clinical Trial. JAMA. JAMA Network
• VINTAGE MI Trial Summary. American College of Cardiology
• Oral L-Arginine Supplementation in Acute Myocardial Infarction Therapy: A Meta-analysis of Randomized Controlled Trials. PMC/NIH
• Rhim HC et al. (2019). The Potential Role of Arginine Supplements on Erectile Dysfunction: A Systemic Review and Meta-Analysis. Journal of Sexual Medicine. ScienceDirect
• Koolwal A et al. (2019). L-arginine and Erectile Dysfunction. Journal of Psychosexual Health. SAGE Journals
• Engelhardt PF et al. (2000). Effectiveness of oral L-arginine in first-line treatment of erectile dysfunction: a controlled crossover study. PubMed
• Viribay A et al. (2020). Effects of Arginine Supplementation on Athletic Performance Based on Energy Metabolism: A Systematic Review and Meta-Analysis. Nutrients. PMC/NIH
• Rezaei S et al. (2021). The effect of L-arginine supplementation on maximal oxygen uptake: A systematic review and meta-analysis. Physiological Reports. Wiley
• Bescós R et al. (2008). No effect of short-term arginine supplementation on nitric oxide production, metabolism and performance in intermittent exercise in athletes. PubMed
• Barbul A et al. (1990). Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery. PubMed
• Arginine-dependent immune responses. PMC/NIH 2021
• Acute L-Arginine supplementation does not increase nitric oxide production in healthy subjects. PMC/NIH
• Effects of prenatal oral L-arginine on birth outcomes: a meta-analysis. PMC/NIH 2021
• Arginine – Wikipedia (for structural and classification overview, cited alongside primary sources)